Big data brings breast cancer research forwards by 'decades'
Scientists have created a ‘map’ linking the shape of breast cancer cells to genes turned on and off, and matched it to real disease outcomes, which could one day help doctors select treatments, according to a study published in Genome Research today (Wednesday).*
In a revolutionary new approach, Cancer Research UK-funded scientists at The Institute of Cancer Research, London, used large sets of data to map out a network of links between cell shape and genes.**
By analysing cell shape in millions of images of more than 300,000 breast cancer cells, and data for more than 28,000 different genes, researchers found that cell shape changes, which can be caused by physical pressures on the tumour,*** are converted into changes in gene activity.
When they then used their maps to analyse thousands of samples taken from women who took part in the Cancer Research UK funded METABRIC study, the researchers discovered that these changes are linked to clinical outcomes for patients.****
They also identified key areas or ‘stations’ within the network that acted as hubs for the flow of information, controlling the levels of many other genes.
Specifically, they found that a protein called NF-kappaB plays a central role in this shape-gene network and could drive the growth and spread of cancer cells. This response was associated with tumour grade in patients and could be used to predict survival.
These findings suggest that because NF-kappaB is rarely faulty in solid tumours, the surrounding mechanical forces are playing a large role in disease progression by switching the gene on.
Dr Chris Bakal, team leader in dynamic cell systems at the Institute of Cancer Research, said: “Our study reveals an exciting link between the forces that act on cancer cells and the development of the disease.
“We used ‘big data’ approaches to carry out a complex analysis that would once have taken decades, in a matter of months.
“The maps we’ve created of cell shapes and their effects on gene activity provide important pointers to new forms of cancer treatment, and ways of making existing therapies more effective.”
Professor Karen Vousden, Cancer Research UK’s chief scientist, said: “Understanding the links between how a breast cancer looks and acts, alongside its genetic makeup, will help researchers develop a more detailed picture of the disease.
“The insights and approaches used in this research could one day lead to us being able to tell from appearance, how aggressive someone's cancer is and how likely to spread, helping doctors decide the best course of treatment.”
For media enquiries please contact the Cancer Research UK press office on +44 203 469 8300 or, out-of-hours, the duty press officer on +44 7050 264 059.
*Sailem, H, Z. & Bakal, C., Identification of clinically predictive metagenes that encode components of a network coupling cell shape to transcription by image-omics’ Genome Research Volume 27, issue 2, February 1, 2017, doi: 10.1101/gr.202028.115
Notes to Editor
**This research used a data set containing cell shape measurements for 307,643 cells across 18 breast cancer cell lines, and a data set describing the expression of 28,376 genes across the same cell lines.
***Cancer cells change their shape to respond to and protect themselves from their surrounding environment. In a tumour, cells are continually pulled, pushed, stretched and squeezed.
****In order to assess the clinical relevance of the shape-gene network, the researchers used breast cancer patient data from the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC). This data set includes expression profiles, clinical features, and disease specific survival for 1981 breast cancer patients.
About the Institute of Cancer Research
The Institute of Cancer Research, London, is one of the world's most influential cancer research organisations.
Scientists and clinicians at The Institute of Cancer Research (ICR) are working every day to make a real impact on cancer patients' lives. Through its unique partnership with The Royal Marsden NHS Foundation Trust and 'bench-to-bedside' approach, the ICR is able to create and deliver results in a way that other institutions cannot. Together the two organisations are rated in the top four centres for cancer research and treatment globally.
The ICR has an outstanding record of achievement dating back more than 100 years. It provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today it is a world leader at identifying cancer-related genes and discovering new targeted drugs for personalised cancer treatment.
A college of the University of London, the ICR is the UK’s top-ranked academic institution for research quality, and provides postgraduate higher education of international distinction. It has charitable status and relies on support from partner organisations, charities and the general public.
The ICR's mission is to make the discoveries that defeat cancer. For more information visit http://www.icr.ac.uk